{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T12:11:03Z","timestamp":1782907863403,"version":"3.54.5"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T00:00:00Z","timestamp":1741651200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/deed.de"},{"start":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T00:00:00Z","timestamp":1741651200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/deed.de"}],"funder":[{"name":"University of Bern"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Urologie"],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title>\n          <jats:sec>\n            <jats:title>Hintergrund<\/jats:title>\n            <jats:p>Seit der Zulassung von Glitazonen als orale Antidiabetika wird kontrovers diskutiert, ob diese das Risiko f\u00fcr Blasenkrebs erh\u00f6hen oder dessen Progression verst\u00e4rken. Aktuelle Daten zeigen, dass Glitazone die Expression von Nectin4 hochregulieren k\u00f6nnen.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Fragestellung<\/jats:title>\n            <jats:p>Diese Ergebnisse machen eine erneute detaillierte Auseinandersetzung mit der Thematik unumg\u00e4nglich. Konsequenterweise f\u00fchrten wir daher eine schnelle Evidenzanalyse durch. Prim\u00e4r sollten systematische \u00dcbersichtsarbeiten gezeigt werden, die diesen Zusammenhang untersuchen. Sekund\u00e4r sollten dann translationale Studien identifiziert werden, die den molekularbiologischen Hintergrund beschreiben.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Material und Methoden<\/jats:title>\n            <jats:p>Es wurde eine schnelle Evidenzanalyse mit Literaturrecherche in MEDLINE via PubMed f\u00fcr den Zeitraum Juli 2000 (Erstzulassung von Glitazonen EU) bis zum Datum der letzten Suche (15.\u00a0Juli 2024) durchgef\u00fchrt.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Ergebnisse<\/jats:title>\n            <jats:p>Die prim\u00e4re Literatursuche ergab 860\u00a0Treffer, schlie\u00dflich konnten 14\u00a0Studien eingeschlossen werden. Davon sind 6\u00a0systematische \u00dcbersichtsarbeiten (5\u00a0inklusive Metaanalyse) und 8\u00a0translationale Studien. In den \u00dcbersichtarbeiten bleibt die Datenlage bzgl. der Assoziation von Glitazonen mit Blasenkrebs uneindeutig, insbesondere durch die Heterogenit\u00e4t der zugrunde liegenden Studien sowie zahlreiche St\u00f6rfaktoren wie Alter oder Raucheranamnese. Ein experimenteller Nachweis eines kausalen Zusammenhangs von Glitazonen und Blasenkrebs konnte nicht erbracht werden. Zwei inkludierte Studien sehen sogar einen m\u00f6glichen therapeutischen Nutzen der Pr\u00e4parate bei diesen Patienten.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Schlussfolgerung<\/jats:title>\n            <jats:p>Es bleibt weiterhin unklar, ob Glitazone in der Entstehung von Harnblasenkarzinomen eine relevante Rolle spielen. Der m\u00f6gliche therapeutische Nutzen sollte dringend weiter untersucht werden.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s00120-025-02557-x","type":"journal-article","created":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T15:06:36Z","timestamp":1741705596000},"page":"669-677","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Der Zusammenhang zwischen Thiazolidinedionen (Glitazonen) und Blasenkrebs: Ein Rapid Review","Association of glitazones and bladder cancer: a\u00a0rapid review"],"prefix":"10.1007","volume":"64","author":[{"given":"Laila","family":"Schneidewind","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Sommerhalder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dario","family":"Willi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cindy","family":"R\u00f6nnau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annemarie","family":"Uhlig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhard","family":"Kiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,11]]},"reference":[{"key":"2557_CR1","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1111\/dme.13854","volume":"36","author":"E Ripamonti","year":"2019","unstructured":"Ripamonti\u00a0E, Azoulay\u00a0L, Abramovicz\u00a0M, Platt\u00a0RW, Siussa\u00a0S (2019) A\u00a0systematic review of observational studies of the association between pioglitazone use and bladder cancer. Diabet Med 36:22\u201335","journal-title":"Diabet Med"},{"key":"2557_CR2","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1007\/s13340-018-0360-4","volume":"10","author":"J Meht\u00e4l\u00e4","year":"2019","unstructured":"Meht\u00e4l\u00e4\u00a0J, Khanfir\u00a0H, Bennett\u00a0D, Ye\u00a0Y, Korhonen\u00a0P, Hoti\u00a0F (2019) Pioglitazone use and risk of bladder cancer: a\u00a0systematic literature review and meta-analysis of observational studies. Diabetol Int 10:24\u201336","journal-title":"Diabetol Int"},{"key":"2557_CR3","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1111\/bcp.12306","volume":"78","author":"RM Turner","year":"2014","unstructured":"Turner\u00a0RM, Kwok\u00a0CS, Chen-Turner\u00a0C, Maduakor\u00a0CA, Singh\u00a0S, Loke\u00a0YK (2014) Thiazolidinediones and associated risk of bladder cancer: a\u00a0systematic review and meta-analysis. Br J Clin Pharmacol 78:258\u2013273","journal-title":"Br J Clin Pharmacol"},{"key":"2557_CR4","first-page":"1","volume":"32","author":"CH Tseng","year":"2014","unstructured":"Tseng\u00a0CH (2014) A\u00a0review on thiazolidinediones and bladder cancer in human studies. J\u00a0Environ Sci Health C Environ Carcinog Ecotoxicol Rev 32:1\u201345","journal-title":"J Environ Sci Health C Environ Carcinog Ecotoxicol Rev"},{"key":"2557_CR5","unstructured":"Bundesinstitut f\u00fcr Arzneimittel und Medizinprodukte (BfArM) https:\/\/www.bfarm.de\/SharedDocs\/Risikoinformationen\/Pharmakovigilanz\/DE\/RI\/2010\/RI-rosiglitazon-anwendungsbeschraenkung.html. Zugegriffen: 30. Okt. 2024"},{"key":"2557_CR6","unstructured":"Bundesinstitut f\u00fcr Arzneimittel und Medizinprodukte (BfArM) https:\/\/www.bfarm.de\/SharedDocs\/Risikoinformationen\/Pharmakovigilanz\/DE\/RI\/2011\/RI-pioglitazon.html. Zugegriffen: 30. Okt. 2024"},{"key":"2557_CR7","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1002\/ijc.10980","volume":"104","author":"R Yoshimura","year":"2003","unstructured":"Yoshimura\u00a0R, Matsuyama\u00a0M, Segawa\u00a0Y, Hase\u00a0T, Mitsuhashi\u00a0M, Tsuchida\u00a0T et\u00a0al (2003) Expression of peroxisome proliferator-activated receptors (PPARs) in human urinary bladder carcinoma and growth inhibition by its agonists. Int J Cancer 104:597\u2013602","journal-title":"Int J Cancer"},{"key":"2557_CR8","first-page":"17","volume-title":"Proceedings of the AACR Special Conference on Bladder Cancer: Transforming the Field","author":"K Chang","year":"2024","unstructured":"Chang\u00a0K, Delavan\u00a0HM, Zhu\u00a0J, Kasap\u00a0C, Yip\u00a0E, Lodha\u00a0R et\u00a0al (2024) Modulating the PPAR\u03b3 pathway to augment NECTIN4-targeting chimeric antigen receptor (CAR) T\u00a0cell therapy [abstract. In: Proceedings of the AACR Special Conference on Bladder Cancer: Transforming the Field, Bd. 30. AACR; Clin Cancer Res 2024, Charlotte, NC. Philadelphia (PA), S\u00a017\u201320 (Abstract nr PR008.)"},{"key":"2557_CR9","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s12961-016-0155-7","volume":"14","author":"MM Haby","year":"2016","unstructured":"Haby\u00a0MM, Chapman\u00a0E, Clark\u00a0R, Barreto\u00a0J, Reveiz\u00a0L, Lavis\u00a0JN (2016) What are the best methodologies for rapid reviews of the research evidence for evidence-informed decision making in health policy and practice: a\u00a0rapid review. Health Res Policy Syst 14:83","journal-title":"Health Res Policy Syst"},{"key":"2557_CR10","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.jclinepi.2009.06.006","volume":"62","author":"A Liberati","year":"2009","unstructured":"Liberati\u00a0A, Altman\u00a0DG, Tetzlaff\u00a0J, Mulrow\u00a0C, Gotzsche\u00a0PC et\u00a0al (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J\u00a0Clin Epidemiol 62:e1\u2013e34","journal-title":"J Clin Epidemiol"},{"key":"2557_CR11","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.diabres.2012.05.006","volume":"98","author":"Z Zhu","year":"2012","unstructured":"Zhu\u00a0Z, Shen\u00a0Z, Lu\u00a0Y, Zhong\u00a0S, Xu\u00a0C (2012) Increased risk of bladder cancer with pioglitazone therapy in patients with diabetes: A\u00a0meta-analysis. Diabetes Res Clin Pract 98:159\u2013163","journal-title":"Diabetes Res Clin Pract"},{"key":"2557_CR12","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1111\/dme.12144","volume":"30","author":"M Ferwana","year":"2013","unstructured":"Ferwana\u00a0M, Firwana\u00a0B, Hasan\u00a0R, Al-Mallah\u00a0MH, Kim\u00a0S, Montor\u00a0VM et\u00a0al (2013) Pioglitazone and risk of bladder cancer: a\u00a0meta-analysis of controlled studies. Diabet Med 30:1026\u20131032","journal-title":"Diabet Med"},{"key":"2557_CR13","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1007\/s00125-014-3456-9","volume":"58","author":"D Levin","year":"2015","unstructured":"Levin\u00a0D, Bell\u00a0S, Sund\u00a0R, Hartikainen\u00a0SA, Tuomileht\u00a0J, Pukkala\u00a0E et\u00a0al (2015) Pioglitazone and bladder cancer risk: a\u00a0multipopulation pooled, cumulative exposure analysis. Diabetologia 58:493\u2013504","journal-title":"Diabetologia"},{"key":"2557_CR14","doi-asserted-by":"publisher","first-page":"15804","DOI":"10.1038\/s41598-017-16074-1","volume":"7","author":"H Qu","year":"2017","unstructured":"Qu\u00a0H, Zheng\u00a0Y, Wang\u00a0Y, Zhang\u00a0R, Ruan\u00a0X, Yang\u00a0G et\u00a0al (2017) Global and Regional Efects of Bladder Cancer Risk Associated with Pioglitazone Therapy in Patients with Diabetes. Sci Rep 7:15804","journal-title":"Sci Rep"},{"key":"2557_CR15","first-page":"254","volume":"123","author":"RA Lubel","year":"2008","unstructured":"Lubel\u00a0RA, Fischer\u00a0SM, Steele\u00a0VE, Julianna\u00a0MM, Desmond\u00a0R, Grubbs\u00a0CJ (2008) Rosiglitazone, a\u00a0PPAR gamma agonist: Potent promoter of hydroxybutyl(butyl)nitrosamine-induced urinary bladder cancers. Int J Cancer 123:254\u2013259","journal-title":"Int J Cancer"},{"key":"2557_CR16","doi-asserted-by":"publisher","first-page":"1109.e1","DOI":"10.1016\/j.urology.2012.12.027","volume":"81","author":"DR Yang","year":"2013","unstructured":"Yang\u00a0DR, Lin\u00a0SJ, Ding\u00a0XF, Miyamoto\u00a0H, Messing\u00a0E, Li\u00a0LQ et\u00a0al (2013) Higher Expression of Peroxisome Proliferator-activated Receptor g or Its Activation by Agonis Thiazolidinedionerosiglitazone Promotes Bladder Cancer Cell Migration and Invasion. Urology 81:1109.e1\u2013e1109.e6","journal-title":"Urology"},{"key":"2557_CR17","doi-asserted-by":"publisher","first-page":"262","DOI":"10.3892\/ijmm.2014.1774","volume":"34","author":"Y Wang","year":"2014","unstructured":"Wang\u00a0Y, Tan\u00a0H, Xu\u00a0D, Ma\u00a0A, Zhang\u00a0L, Sun\u00a0J et\u00a0al (2014) The combinatory effects of PPAR\u2011\u03b3 agonist and survivin inhibition on the cancer stem-like phenotype and cell proliferation in bladder cancer cells. Int J Mol Med 34:262\u2013264","journal-title":"Int J Mol Med"},{"key":"2557_CR18","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1038\/cgt.2014.16","volume":"21","author":"S Yan","year":"2014","unstructured":"Yan\u00a0S, Yang\u00a0Y, Chen\u00a0T, Xi\u00a0Z, Jiang\u00a0X (2014) The PPAR\u03b3 agonist Troglitazone induces autophagy, apoptosis and necroptosis in bladder cancer cells. Cancer Gene Ther 21:188\u2013193","journal-title":"Cancer Gene Ther"},{"key":"2557_CR19","doi-asserted-by":"publisher","first-page":"228","DOI":"10.7150\/ijms.22408","volume":"15","author":"S Yang","year":"2018","unstructured":"Yang\u00a0S, Wang\u00a0J, Chen\u00a0M, Xu\u00a0L, Li\u00a0N, Luo\u00a0Y et\u00a0al (2018) Pioglitazone Use and Risk of Bladder Cancer: an In Vitro Study. Int J Med Sci 15:228\u2013237","journal-title":"Int J Med Sci"},{"key":"2557_CR20","doi-asserted-by":"publisher","first-page":"29","DOI":"10.5213\/inj.1938186.093","volume":"24","author":"M Shahid","year":"2020","unstructured":"Shahid\u00a0M, Kim\u00a0M, Yeon\u00a0A, Jin\u00a0P, Kim\u00a0WK, You\u00a0S et\u00a0al (2020) Pioglitazone Alters the Proteomes of Normal Bladder Epithelial Cells but Shows No Tumorigenic Effects. Int Neurourol\u00a0J 24:29\u201340","journal-title":"Int Neurourol J"},{"key":"2557_CR21","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1002\/em.22424","volume":"62","author":"ZA Sekeroglu","year":"2021","unstructured":"Sekeroglu\u00a0ZA, Sekeroglu\u00a0V, Yedier\u00a0SK, Ilkun\u00a0E, Liou\u00a0LS (2021) Increased DNA strand breaks and neoplastic transformation in human bladder cells treated with pioglitazone. Environ Mol Mutagen 62:143\u2013154","journal-title":"Environ Mol Mutagen"},{"key":"2557_CR22","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.1038\/s41388-022-02235-8","volume":"41","author":"SC Baker","year":"2022","unstructured":"Baker\u00a0SC, Mason\u00a0AS, Slip\u00a0RG, Skinner\u00a0KT, Macdonald\u00a0A, Masood\u00a0O et\u00a0al (2022) Induction of APOBEC3-mediated genomic damage in urothelium implicates BK polyomavirus (BKPyV) as a\u00a0hit-and-run driver for bladder cancer. Oncogene 41:2139\u20132151","journal-title":"Oncogene"},{"key":"2557_CR23","unstructured":"Teva Pharma europ\u00e4ische Zulassung f\u00fcr Pioglitazone. https:\/\/ec.europa.eu\/health\/documents\/community-register\/2016\/20161118136398\/anx_136398_de.pdf. Zugegriffen: 31. Okt. 2024"},{"key":"2557_CR24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/17425255.2024.2316131","volume":"20","author":"HY Chen","year":"2024","unstructured":"Chen\u00a0HY, Zhao\u00a0H, Yang\u00a0JJ, Zhang\u00a0Q, Yan\u00a0MM, Qui\u00a0XY et\u00a0al (2024) Reassessment of pioglitazone and bladder cancer based on FAERS database. Expert Opin Drug Saf 20:1\u20138","journal-title":"Expert Opin Drug Saf"}],"container-title":["Die Urologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-025-02557-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00120-025-02557-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-025-02557-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T11:18:02Z","timestamp":1750936682000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00120-025-02557-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,11]]},"references-count":24,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["2557"],"URL":"https:\/\/doi.org\/10.1007\/s00120-025-02557-x","relation":{},"ISSN":["2731-7064","2731-7072"],"issn-type":[{"value":"2731-7064","type":"print"},{"value":"2731-7072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,11]]},"assertion":[{"value":"13 February 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"L.\u00a0Schneidewind, B.\u00a0Sommerhalder, D.\u00a0Willi, C.\u00a0R\u00f6nnau, A.\u00a0Uhlig und B.\u00a0Kiss geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}